LYC001 / Liangyuan Bioscience - LARVOL DELTA

LYC001, a high-affinity hierarchical assembly for lymph node-targeted IL-2 immunotherapy: Preclinical validation of potent antitumor immunity and preliminary safety from the first-in-human phase Ia study (AACR 2026) - P | "The drug was well-tolerated with no dose-limiting toxicities (DLTs) or signs of VLS. Enrollment is ongoing, and updated dose-escalation data will be presented."

First-in-human • P1 data • Preclinical • Genito-urinary Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • CD8 • IL2

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (clinicaltrials.gov) - P1/2 | N=600 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

IO biomarker • New P1/2 trial • Oncology • Solid Tumor